<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005237</url>
  </required_header>
  <id_info>
    <org_study_id>1118</org_study_id>
    <secondary_id>R01HL040392</secondary_id>
    <nct_id>NCT00005237</nct_id>
  </id_info>
  <brief_title>Epidemiology of Symptomatic Arrhythmias</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <brief_summary>
    <textblock>
      To acquire a better understanding of the spontaneous clinical behavior of paroxysmal&#xD;
      tachycardia by studying epidemiologic features of symptomatic tachycardia patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      Paroxysmal arrhythmias are a group of disorders in which sudden abnormalities of the cardiac&#xD;
      rhythm occur without warning. Despite the abundant information available from studies on the&#xD;
      mechanisms of tachycardias, there was hardly a shred of objective data in 1989 to establish&#xD;
      how the occurrence of symptomatic tachycardias was influenced by various mechanisms. In fact,&#xD;
      there were very few objective data describing the occurrence of symptomatic tachycardia among&#xD;
      the patients who were afflicted with various paroxysmal tachycardias. For example, were&#xD;
      patients in normal sinus rhythm likely to remain free of their tachycardia for one day, one&#xD;
      week, one month, or longer? The suddenness and apparent unpredictability of attacks of&#xD;
      paroxysmal tachycardias have been substantial obstacles to quantitative description of their&#xD;
      occurrence. These studies used careful documentation of spontaneous tachycardia to establish&#xD;
      the epidemiology of symptomatic arrhythmias.&#xD;
&#xD;
      DESIGN NARRATIVE:&#xD;
&#xD;
      Baseline electrophysiologic methods, including intracardiac recording and programmed&#xD;
      electrical stimulation, were used to determine the mechanism of paroxysmal supraventricular&#xD;
      tachycardia. All patients had antiarrhythmic medications stopped. In most cases, the&#xD;
      diagnosis of atrial fibrillation was established by scalar electrocardiographic criteria. At&#xD;
      the time of entry into follow-up each patient was given a cardiobeeper and instructed to&#xD;
      record and transmit any symptomatic arrhythmia when it occured. Descriptive information about&#xD;
      each patient was entered into a baseline data file which included information on the time&#xD;
      interval between attacks, age, sex, mechanism of arrhythmia, types of associated heart&#xD;
      diseases, ECG data during sinus rhythm, and date and time of call. The purpose of the&#xD;
      outpatient follow-up was to obtain objective documentation of spontaneously occurring,&#xD;
      symptomatic tachycardia for quantitative analyses. Holter monitoring was used in patients&#xD;
      with paroxysmal tachycardias to establish that asymptomatic tachycardia did not occur so&#xD;
      often that it constituted an important, unrecognized feature of these clinical conditions.&#xD;
&#xD;
      Ten consecutively referred patients with paroxysmal supraventricular tachycardia and ten&#xD;
      consecutively referred patients with atrial fibrillation underwent untreated surveillance&#xD;
      with telephone/ cardiobeeper monitoring for symptomatic arrhythmias and had four 24-hour&#xD;
      ambulatory ECGs recorded at weekly intervals to detect symptomatic and asymptomatic&#xD;
      arrhythmias. The Cox proportional hazards model was used to test the hypothesis that the&#xD;
      mechanism of tachycardia was the most important predictor of the tachycardia-free period&#xD;
      during an untreated observation period.&#xD;
&#xD;
      The study completion date listed in this record was obtained from the &quot;End Date&quot; entered in&#xD;
      the Protocol Registration and Results System (PRS) record.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1988</start_date>
  <completion_date type="Actual">November 1993</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Arrhythmia</condition>
  <condition>Tachycardia</condition>
  <condition>Tachycardia, Supraventricular</condition>
  <eligibility>
    <criteria>
      <textblock>
        No eligibility criteria&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Riley RD, Pritchett EL. Pharmacologic management of atrial fibrillation. J Cardiovasc Electrophysiol. 1997 Jul;8(7):818-29. doi: 10.1111/j.1540-8167.1997.tb00841.x.</citation>
    <PMID>9255690</PMID>
  </reference>
  <reference>
    <citation>Hamer ME, Wilkinson WE, McCarthy EA, Page RL, Pritchett EL. Heart rate during spontaneous and induced paroxysmal supraventricular tachycardia. Pacing Clin Electrophysiol. 1995 Dec;18(12 Pt 1):2155-7. doi: 10.1111/j.1540-8159.1995.tb04641.x.</citation>
    <PMID>8771127</PMID>
  </reference>
  <reference>
    <citation>Pritchett ELC: Afternoon Arrhythmia. Med Aspects Human Sex, 23:16, January 1989</citation>
  </reference>
  <reference>
    <citation>Greer GS, Wilkinson WE, McCarthy EA, Pritchett EL. Random and nonrandom behavior of symptomatic paroxysmal atrial fibrillation. Am J Cardiol. 1989 Aug 1;64(5):339-42. doi: 10.1016/0002-9149(89)90531-6.</citation>
    <PMID>2756878</PMID>
  </reference>
  <reference>
    <citation>Vitullo RN, Wharton JM, Allen NB, Pritchett EL. Trazodone-related exercise-induced nonsustained ventricular tachycardia. Chest. 1990 Jul;98(1):247-8. doi: 10.1378/chest.98.1.247.</citation>
    <PMID>2361400</PMID>
  </reference>
  <reference>
    <citation>Linzer M, Pritchett EL, Pontinen M, McCarthy E, Divine GW. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol. 1990 Jul 15;66(2):214-9. doi: 10.1016/0002-9149(90)90591-n.</citation>
    <PMID>2371954</PMID>
  </reference>
  <reference>
    <citation>Linzer M, Pontinen M, Gold DT, Divine GW, Felder A, Brooks WB. Impairment of physical and psychosocial function in recurrent syncope. J Clin Epidemiol. 1991;44(10):1037-43. doi: 10.1016/0895-4356(91)90005-t.</citation>
    <PMID>1940996</PMID>
  </reference>
  <reference>
    <citation>Weiner HL, McCarthy EA, Pritchett EL. Regular ventricular rhythms in patients with symptomatic paroxysmal atrial fibrillation. J Am Coll Cardiol. 1991 May;17(6):1283-7. doi: 10.1016/s0735-1097(10)80136-6.</citation>
    <PMID>2016444</PMID>
  </reference>
  <reference>
    <citation>Clair WK, Wilkinson WE, McCarthy EA, Pritchett EL. Treatment of paroxysmal supraventricular tachycardia with oral diltiazem. Clin Pharmacol Ther. 1992 May;51(5):562-5. doi: 10.1038/clpt.1992.63.</citation>
    <PMID>1587069</PMID>
  </reference>
  <reference>
    <citation>Pritchett EL, Wilkinson WE. New drug application strategies for supraventricular arrhythmias. Clin Pharmacol Ther. 1991 May;49(5):481-7. doi: 10.1038/clpt.1991.58. No abstract available.</citation>
    <PMID>2029826</PMID>
  </reference>
  <reference>
    <citation>Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991 Apr 1;114(7):539-44. doi: 10.7326/0003-4819-114-7-539.</citation>
    <PMID>2001087</PMID>
  </reference>
  <reference>
    <citation>Hamer ME, Clair WK, Wilkinson WE, Greenfield RA, Pritchett EL, Page RL. Evaluation of outpatients experiencing implantable cardioverter defibrillator shocks associated with minimal symptoms. Pacing Clin Electrophysiol. 1994 May;17(5 Pt 1):938-43. doi: 10.1111/j.1540-8159.1994.tb01436.x.</citation>
    <PMID>7517528</PMID>
  </reference>
  <reference>
    <citation>Hamer ME, Wilkinson WE, Clair WK, Page RL, McCarthy EA, Pritchett EL. Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 1995 Apr;25(5):984-8. doi: 10.1016/0735-1097(94)00512-o.</citation>
    <PMID>7897142</PMID>
  </reference>
  <reference>
    <citation>Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchett EL. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol. 1994 Oct 15;74(8):826-9. doi: 10.1016/0002-9149(94)90448-0. No abstract available.</citation>
    <PMID>7942563</PMID>
  </reference>
  <reference>
    <citation>Linzer M, Gold DT, Pontinen M, Divine GW, Felder A, Brooks WB. Recurrent syncope as a chronic disease: preliminary validation of a disease-specific measure of functional impairment. J Gen Intern Med. 1994 Apr;9(4):181-6. doi: 10.1007/BF02600121.</citation>
    <PMID>8014722</PMID>
  </reference>
  <reference>
    <citation>Pritchett EL. Management of atrial fibrillation. N Engl J Med. 1992 May 7;326(19):1264-71. doi: 10.1056/NEJM199205073261906. No abstract available.</citation>
    <PMID>1560803</PMID>
  </reference>
  <verification_date>May 2000</verification_date>
  <study_first_submitted>May 25, 2000</study_first_submitted>
  <study_first_submitted_qc>May 25, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2000</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Supraventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

